RomaniaTuberculosis profile
Population  2014 20 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.1 (1.1–1.1) 5.5 (5.5–5.5)
Mortality (HIV+TB only) 0.054 (0.035–0.077) 0.27 (0.18–0.39)
Prevalence  (includes HIV+TB) 20 (8–36) 99 (41–184)
Incidence  (includes HIV+TB) 16 (14–18) 81 (71–91)
Incidence (HIV+TB only) 0.51 (0.44–0.59) 2.6 (2.2–3)
         
Case detection, all forms (%) 94 (83–110)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.8 (1.8–4.2) 11 (8–15)
MDR-TB cases among notified pulmonary
TB cases
290 (190–430) 360 (270–480)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 7 874   1 899
Pulmonary, clinically diagnosed 2 421   356
Extrapulmonary 2 209   102
       
Total new and relapse 14 861    
Previously treated, excluding relapses 1 045    
Total cases notified 15 906    
Among 14 861 new and relapse cases:
639 (4%) cases aged under 15 years; male:female ratio: 2.1
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 5 751 (73%) 2 171 (64%) 7 922
Laboratory-confirmed RR-/MDR-TB cases     578
Patients started on MDR-TB treatment ***     648
TB/HIV 2014 Number (%)
TB patients with known HIV status 10 927 (69)
HIV-positive TB patients 312 (3)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 281 (90)
HIV-positive TB patients on antiretroviral therapy (ART) 278 (89)
HIV-positive people screened for TB 316  
HIV-positive people provided with IPT 158  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (85) 15 188
Previously treated cases, excluding relapse, registered in 2013 (45) 925
HIV-positive TB cases, all types, registered in 2013 (58) 250
RR-/MDR-TB cases started on second-line treatment in 2012 (34) 638
XDR-TB cases started on second-line treatment in 2012 (7) 41
Laboratories 2014  
Smear (per 100 000 population) 0.5
Culture (per 5 million population) 23.2
Drug susceptibility testing (per 5 million population) 11.2
Sites performing Xpert MTB/RIF 3
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 18
% Funded domestically 15%
% Funded internationally 67%
% Unfunded 18%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-07-29 Data: www.who.int/tb/data